TransMedics is experiencing a slowdown in liver transplant growth, increasing its reliance on international markets and other organ transplants like heart, lung, and kidney to drive future growth. Delays in heart and lung clinical trials have created uncertainty, but successful trial completions within 12 to 18 months could boost momentum. The company’s long-term prospects remain strong, especially with its OCS Kidney product, but effective execution in new treatment areas and European markets is crucial to maintaining its valuation.
As TransMedics navigates challenges in clinical trials and shifts focus to international markets and new organ transplants, its stock price on Pluang remains steady at USD 86.61 as of Sep 18, 2026 15:31 WIB. The company’s market cap stands at $3.04 billion, with a slight 1-day decline of 0.06%. Investor sentiment on Pluang shows a majority leaning towards buying, with 72% of orders favoring purchases over sales.
